GRAALL2014 (FL)

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients

Study treatments

Nelarabine during consolidation and maintenance

Inclusion criteria

• Whose blood and bone marrow explorations have been completed before the steroids prephase
• aged 18-59 years old with a not previously treated (including IT injection) T-ALL newly-diagnosed according to the WHO 2008 definition with > 20% bone marrow blasts
• ECOG performance status < 3

Exclusion criteria

• With lymphoblastic lymphoma and bone marrow blasts < 20%, Burkitt-type ALL or with antecedents of chronic myeloid leukemia (CML) or other myeloproliferative neoplasm

• With contra-indication to anthracyclines or any other general or visceral contra-indication to intensive therapy except if considered related to the ALL:

Participating sites

• Cliniques Universitaires Saint-Luc